Latest Conference Articles

The oncolytic virus T-VEC showed consistent improvements at 5 years for patients with stage IIIB to IVM1a melanoma.

Adding abemaciclib to trastuzumab improved overall survival in women with with hormone receptor–positive, HER2-positive advanced breast cancer, according to new findings discussed at the 2022 ESMO Congress.

Data from the Defi trial shows that nirogacestat had a significant reduction in the risk of disease progression for patients with progressive desmoid tumors.

A novel tumor-infiltrating lymphocyte therapy showed a 50% reduction in the risk of death for patients with stage IIIC/IV unresectable, treatment-refractory melanoma.

A study of air pollutant particulate matter shows that it may be a mechanistic driver for lung cancer, showing a need to curb its source.

Although the combination use of lenvatinib plus pembrolizumab did not induce statistically significant differences in the co-primary end points, the LEAP-002 trial induced the longest seen median overall survival with lenvatinib monotherapy in patients with unresectable HCC.

Findings presented at ESMO 2022 show the survival benefits of camrelizumab plus rivoceranib in patients with unresectable HCC.

The phase 2 DAWNA-2 trial of dalpiciclib plus letrozole or anastrozole led to a reduced the risk of disease progression vs chemotherapy alone in patients with treatment-naïve, hormone receptor–positive, HER2-negative advanced breast cancer.

The investigational carcinoembryonic antigen claudin 6–directed CAR T-cell therapy BNT211-01 displayed clinical activity in combination with a CLDN6-encoding mRNA vaccine in patients with CLDN6-positive relapsed/refractory advanced solid tumors.

Oleclumab plus durvalumab and chemotherapy did not increase clinical benefit rate for patients with advanced triple-negative breast cancer, according to results from the phase 2 SYNERGY trial.

Treatment with sactiuzumab govitecan improved overall survival, objective response rate, duration of response, and overall quality of life vs physician’s choice in the phase 3 TROPiCS-02 study.

The phase 2 NEOpredict trial of nivolumab with or without relatilmab met its primary end point of feasibility of treatment in patients with resectable non–small cell lung cancer.

Rhenium-186 nanoliposome at doses exceeding 100 Gy showed promising results in patients with recurrent glioma, according to phase 1 findings from the ReSPECT-GBM trial presented at ESMO 2022.

Updated findings of the MONARCH 3 trial of abemaciclib added to a nonsteroidal aromatase inhibitor presented at ESMO 2022 revealed prolonged overall survival in hormone receptor-positive, HER2-negative breast cancer.

Findings from the phase 3 SOLO1/GOG-3004 trial presented at ESMO 2022 support maintenance therapy with olaparib in women with newly diagnosed advanced ovarian cancer.

Findings from the phase 3 ARIEL4 trial of rucaparib vs chemotherapy in relapsed ovarian cancer with deleterious BRCA1/2 mutations raised questions about optimal sequencing of PARP inhibitors at ESMO 2022.

Adding olaparib to bevacizumab maintenance therapy following treatment with first-line standard-of-care treatment revealed am improvement in overall survival in advanced ovarian cancer and homologous recombination deficiency.

The phase 2 CARTITUDE study showed encouraging response in the heavily-pretreated multiple myeloma population. Now, the phase 3 CARTITUDE-4 trial is underway.

An association between biallelic deletion of TNFRSF17 and resistance to therapies like chimeric antigen receptor T cells and T-cell engagers has been identified in myeloma.

The combination of daratumumab plus lenalidomide, bortezomib, and dexamethasone continued to show superior efficacy in patients with newly diagnosed multiple myeloma based on the GRIFFIN trial's final analysis reported at the 19th International Myeloma Society annual meeting.

Results of a phase 1 trial of the bispecific antibody ABBV-383 showed a high overall response rate and manageable adverse event profile in patients with relapsed/refractory multiple myeloma.

Results shown from studies of bispecific antibodies, immunomodulatory drugs , and antibody-drug conjugates signal a bright future for relapsed or refractory myeloma treatment.

No significant survival differences were shown between 2 high-dose regimens for newly diagnosed multiple myeloma. However, certain prognostic factors may improve or decrease survival.

Patients with relapsed or refractory multiple myeloma who relapsed after treatment with B-cell maturation antigen–directed chimeric antigen receptor T-cell therapy.

Final overall survival in the ICARIA-MM study favored the combination of Isatuximab-irfc plus pomalidomide and low-dose dexamethasone.

Updated analysis results of from the IKEMA showed improvement in the depth of response to isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma.

In LINKER-MM1 study, responses to REGN5458 occurred early, were durable, and deepened over time.

Post-hoc analysis findings from phase 2 DREAMM-2 trial show no relationship between ocular conditions found at baseline in patients with relapsed or refractory multiple myeloma and ocular toxicity from belantamab mafodotin.

Heinz Ludwig, MD, discusses the incidence of increased infections in patients with multiple myeloma.

Data presented at the 19th International Myeloma Society Annual Meeting show that carfilzomib plus lenalidomide and dexamethasone after transplant prolongs progression-free survival compared with lenalidomide alone in patients with myeloma.